Clinical Trial Update: Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas [Phase 1, Phase 2]

View source ↗

Summary

The National Cancer Institute is sponsoring Phase 1/2 trials evaluating the CDK4/6 inhibitor abemaciclib for Neurofibromatosis type I–related atypical neurofibr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type

Drugs mentioned

• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neurofibromatosis 1 | Phase 1, Phase 2 | Status: RECRUITING